| Be it enacted by the People of the State of Maine as follows: |
|
| | Sec. 1. 22 MRSA §3174-DD is enacted to read: |
|
| §3174-DD.__Drug Utilization Review Committee |
|
| | 1.__Authority.__The department has the authority to | determine which prescription and over-the-counter drugs are | subject to prior authorization and coverage under the | MaineCare program. |
|
| | 2.__Drug Utilization Review Committee.__In order to make | determinations regarding which prescription and over-the- | counter drugs are subject to prior authorization, the Drug | Utilization Review Committee, referred to in this section as | "the committee," is established. |
|
| A.__The committee is composed of an equal number of | actively practicing physicians and actively practicing | pharmacists, totaling not fewer than 6 individuals.__The | department shall appoint the members of the committee and | establish their terms. |
|
| B.__Public notice of the date, time and location of all | meetings of the committee must be made in accordance with | Title 1, section 406 at least 7 days in advance of the | meeting.__This notice must also include a list of all | drugs to be considered for prior authorization at that | meeting.__The meetings must be considered public | proceedings, for purposes of Title 1, chapter 13.__Members | of the public, including health care providers and drug | manufacturers, who are physically present at committee | meetings must be granted reasonable opportunity to address | the committee prior to any vote. |
|
| C.__At the conclusion of a meeting pursuant to paragraph | B, committee members shall record their vote for each drug | on a form to be supplied at each meeting.__After adding or | deleting a drug from the list of drugs that require prior | authorization, the committee shall issue written findings | setting forth the evidentiary basis for its decision.__ | These findings must address, without limitation, all | relevant clinical data, as well as the likelihood that | subjecting a drug to prior authorization will cause | adverse medical results or affect patients' access to all | medically necessary outpatient drugs.__A vote of at least | 2/3 of the committee members present is required to add or | delete a drug from the list of drugs that require prior | authorization. |
|
|